Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.

Autophagy confers de novo resistance to PARP inhibitor, talazoparib. Autophagy inhibition improves the therapeutic outcome of PARPi treatment in preclinical mice model, bearing HR-proficient breast tumours, warranting its usage in the clinical settings.